Viking Therapeutics Prices Concurrent Public Offerings Of 7,857,143 Shares At $35/Shr And $225M Aggregate Principal Amount Of 2.00% Convertible Senior Notes Due 2032
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent
Viking Therapeutics is raising money by selling new shares and bonds. This gives them cash to pay for medicine research, so watch if they use it well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.